Ascendis Pharma A-S

Yahoo Finance • yesterday

Former Novo Nordisk Executive Jesper Høiland Joins Alva Therapeutics' Board of Directors

MILPITAS, Calif., Dec. 3, 2025 /PRNewswire/ -- Alva Therapeutics, Inc. ("Alva") a company developing a novel oral incretin secretagogue based therapy for the treatment of Type 2 diabetes and obesity—announced that Mr. Jesper Høiland has be... Full story

Yahoo Finance • 6 days ago

Ascendis dwarfism drug candidate review extended by FDA

[FDA headquarters in Washington DC.] JHVEPhoto * The US FDA has extended the review time of an NDA for Ascendis Pharma's (ASND [https://seekingalpha.com/symbol/ASND]) TransCon CNP (navepegritide), a treatment for children with achondrop... Full story

Yahoo Finance • 8 days ago

European Equities Traded in the US as American Depositary Receipts Surge in Wednesday Trading

European equities traded in the US as American depositary receipts were surging higher late Wednesda PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 9 days ago

Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia

–  Prescription Drug User Fee Act (PDUFA) goal date extended by three months to February 28, 2026 COPENHAGEN, Denmark, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the U.S. Food & Drug Admini... Full story

Yahoo Finance • 9 days ago

European Equities Traded in the US as American Depositary Receipts Turn Sharply Higher in Tuesday Trading

European equities traded in the US as American depositary receipts were sharply higher late Tuesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 17 days ago

Results of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics

COPENHAGEN, Denmark, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that pivotal Week 52 results from its randomized double-blind, placebo-controlled ApproaCH Trial of investigational once-weekly Tra... Full story

Yahoo Finance • 20 days ago

Liberty All-Star® Growth Fund, Inc. October 2025 Monthly Update

BOSTON, November 14, 2025--(BUSINESS WIRE)--Below is the October 2025 Monthly Update for the Liberty All-Star Growth Fund, Inc. (NYSE: ASG). Liberty All-Star Growth Fund, Inc. Ticker: ASG Monthly Update, October 2025 Investment Approac... Full story

Yahoo Finance • 22 days ago

Ascendis Pharma GAAP EPS of - €1.00, revenue of €143.1M

* Ascendis Pharma press release [https://seekingalpha.com/pr/20304985-ascendis-pharma-reports-third-quarter-2025-financial-results] (ASND [https://seekingalpha.com/symbol/ASND]): Q3 GAAP EPS of - €1.00. * Revenue of €143.1M. * As of... Full story

Yahoo Finance • 22 days ago

Ascendis Pharma Reports Third Quarter 2025 Financial Results

–   Q3 2025 revenue of €143.1 million for YORVIPATH® and €50.7 million for SKYTROFA® –   Q3 2025 operating profit of €11.0 million –   TransCon® CNP (navepegritide) under FDA Priority Review for the treatment of children with achondropla... Full story

Yahoo Finance • 22 days ago

After-Hours Earnings Report for November 12, 2025 : CSCO, MFC, FLUT, PAAS, ASND, TTEK, CLBT, CELC, GRAL, DLO, LB, WBTN

The following companies are expected to report earnings after hours on 11/12/2025. Visit our Earnings Calendar for a full list of expected earnings releases. Cisco Systems, Inc. (CSCO)is reporting for the quarter ending October 31, 202... Full story

Yahoo Finance • 27 days ago

New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism

COPENHAGEN, Denmark, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that a new pooled analysis showed sustained and clinically meaningful improvements in renal function in adults with hypoparathyroid... Full story

Yahoo Finance • last month

Ascendis Pharma struggles after report of Yorvipath patient death

[Dark, death and body of person in hospital on bed for healthcare, medical or tragic accident. Eternity, mortality and rest with cadaver of patient in clinic for afterlife, emergency or mistake] Sean Anthony Eddy/E+ via Getty Images * A... Full story

Yahoo Finance • 2 months ago

European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading

European equities traded in the US as American depositary receipts were trending lower late Thursday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 months ago

Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with Achondroplasia

COPENHAGEN, Denmark, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TransCon CNP (navepegritide... Full story

Yahoo Finance • 2 months ago

European Equities Traded in the US as American Depositary Receipts Edge Higher in Tuesday Trading

European equities traded in the US as American depositary receipts were tracking slightly higher Tue PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 3 months ago

Ascendis to Share Latest Endocrinology Rare Disease Data in 3 Oral Presentations at ASBMR 2025

COPENHAGEN, Denmark, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced three oral presentations of its latest achondroplasia and hypoparathyroidism data at ASBMR 2025, the annual meeting of the America... Full story

Yahoo Finance • 3 months ago

European Equities Traded in the US as American Depositary Receipts Start Week Sharply Lower in Tuesday Trading

European equities traded in the US as American depositary receipts were sharply lower late Tuesday m PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 3 months ago

ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) Combines Technical Strength and High-Growth Momentum

In the world of growth investing, combining technical strength with fundamental momentum often yields strong opportunities. One approach gaining traction with traders is the integration of Mark Minervini’s Trend Template, a systematic meth... Full story

Yahoo Finance • 3 months ago

Ascendis Pharma to Participate in the 2025 Wells Fargo Healthcare Conference

COPENHAGEN, Denmark, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3... Full story

Yahoo Finance • 3 months ago

Earnings call transcript: Ascendis Pharma Q2 2025 beats EPS forecasts

Ascendis Pharma reported its Q2 2025 earnings, revealing a significant earnings per share (EPS) beat with an actual EPS of -0.82 compared to the forecast of -1.27, marking a surprise of 35.43%. Revenue also surpassed expectations, reaching... Full story